NCT05945394

Brief Summary

To evaluate the association of surem TRAF3IP2 levels with the atherosclerotic plaque development in human

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
800

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Sep 2023

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 29, 2023

Completed
15 days until next milestone

First Posted

Study publicly available on registry

July 14, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

September 1, 2023

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2023

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

September 13, 2023

Status Verified

September 1, 2023

Enrollment Period

2 months

First QC Date

June 29, 2023

Last Update Submit

September 8, 2023

Conditions

Coronary Heart Disease, Susceptibility to, 1

Keywords

TRAF3IP2, Coronary angiography, coronary deart disease

Outcome Measures

Primary Outcomes (1)

  • stenosis of coronary artery

    The stenosis of coronary artery based on the results of coronary angiography

    1 week

Secondary Outcomes (1)

  • coronary artery calcium

    1 week

Study Arms (1)

Patients with suspected CHD who experienced CAG

Patients with suspected coronary heart disease who experienced coronary angiography

Other: No intervention

Interventions

No interventionOTHER

This is an obvertional study, and there is no intervention.

Patients with suspected CHD who experienced CAG

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with suspected coronary heart disease who experienced coronary angiography

You may qualify if:

  • Patients with suspected coronary heart disease
  • patients received coronary angiography

You may not qualify if:

  • NYHA III-IV
  • malignant tumor
  • acute infection
  • thyroid dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Huai'an First People's Hospital

Huai'an, Jiangsu, 223300, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

The blood sample will be collected, and the surem TRAF3IP2 levels will be measured using ELASA.

MeSH Terms

Conditions

Coronary Disease

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Ma Shuren, MD

    NJMU

    STUDY DIRECTOR

Central Study Contacts

Geng Jin, MD

CONTACT

+86-17753124846gj885258@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
associate doctor

Study Record Dates

First Submitted

June 29, 2023

First Posted

July 14, 2023

Study Start

September 1, 2023

Primary Completion

October 31, 2023

Study Completion

December 31, 2023

Last Updated

September 13, 2023

Record last verified: 2023-09

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)